Given the potential consequences of gene heterogeneity, nine patients with ALS carrying pathogenic variants were excluded in our study, hitherto, there has been no relevant research concerning the impact of the TARDBP mutation on the levels of TDP-43 in CSF and plasma in ALS patients. Here, TARDBP is linked to amyotrophic lateral sclerosis.